2021年2月21日 · This phase I study assessed the safety, tolerability, preliminary antitumor activity, and preliminary biomarkers of ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed for tumor microenvironment-dependent …

The results from our study of LB-1 were used to develop a human cross-reactive bispecific molecule (ABBV-428) that targeted human CD40 and mesothelin. ABBV-428 demonstrated enhanced activation of antigen-presenting cells and T cells upon binding to cell-surface mesothelin, and inhibition of cultured or implanted PC3 tumor cell growth after ...

ABBV-428 is a bispecific antibody that targets mesothelin via a C-terminal single-chain variable fragment flanking Fc-modified human IgG1 and CD40 via an N-terminal single-chain variable fragment.

ABBV-428 represents a class of bispecific molecules with conditional activity dependent on the binding of a tumor-specific antigen, and such activity could potentially maximize antitumor potency while limiting systemic toxicity in clinical studies.

2021年2月19日 · ABBV-428 is a bispecific antibody that targets mesothelin via a C-terminal single-chain variable fragment flanking Fc-modified human IgG1 and CD40 via an N-terminal single-chain variable fragment.

2022年5月24日 · 小结： abbv-428结合并激活血液中的cd40， 导致b细胞激活 。 sd患者中观察到炎症免疫肿瘤微环境的证据。

该 I 期研究评估了 ABBV-428 的安全性、耐受性、初步抗肿瘤活性和初步生物标志物，ABBV-428 是一流的间皮素靶向双特异性抗体，专为肿瘤微环境依赖性 CD40 激活而设计，具有有限的全身毒性。 方法 每 2 周对晚期实体瘤患者进行一次 ABBV-428 静脉内给药。 加速滴定（从 0. 01 mg/kg 剂量）和 3+3 剂量递增方案，随后在卵巢癌和间皮瘤（与高间皮素表达相关的肿瘤类型）中推荐的 II 期剂量队列扩展。 结果 59 名患者接受了 0.01 至 3.6 mg/kg 之间的剂量治疗。 未达到最大耐 …

abbv-428已被证实在肿瘤抗原存在时，能有效激活cd40，目前针对实体肿瘤的i期临床试验正在进行中。 靶向阿尔法疗法 靶向钍-227结合物（TTC）代表一种TAT亚型，由共价连接的3,2-HOPO螯合剂与特定抗体组成，以确保钍-227传递到表达间皮素的细胞。

2021年2月1日 · This phase I study assessed the safety, tolerability, preliminary antitumor activity, and preliminary biomarkers of ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed...

ABBV-428 is a bispecific antibody that targets meso- thelin via a C-terminal single-chain variable fragment flanking Fc- modified human IgG1 and CD40 via an N- ter-